Evidence map›Paper›PMID 35725860›Full record

ArticleScientific reports2022

Presence of rare potential pathogenic variants in subjects under 65 years old with very severe or fatal COVID-19.

Rosario López-Rodríguez, Marta Del Pozo-Valero, Marta Corton, Pablo Minguez, Javier Ruiz-Hornillos, María Elena Pérez-Tomás, María Barreda-Sánchez, Esther Mancebo, Cristina Villaverde, Gonzalo Núñez-Moreno and 6 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 16 institutions in 1 country.

Rosario López-RodríguezDepartment of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
Marta Del Pozo-ValeroDepartment of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
Marta CortonDepartment of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
Pablo MinguezDepartment of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.ORCID 0000-0003-4099-9421
Javier Ruiz-HornillosAllergy Unit, Hospital Infanta Elena, Valdemoro, Madrid, Spain.
María Elena Pérez-TomásInstituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca (IMIB-Arrixaca), Murcia, Spain.
María Barreda-SánchezInstituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca (IMIB-Arrixaca), Murcia, Spain.
Esther ManceboDepartment of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Cristina VillaverdeDepartment of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
Gonzalo Núñez-MorenoDepartment of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
Raquel RomeroDepartment of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
STOP_Coronavirus Study Group
Estela Paz-ArtalDepartment of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Encarna Guillén-NavarroCenter for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029, Madrid, Spain.
Berta AlmogueraDepartment of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
Carmen AyusoDepartment of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain. cayuso@fjd.es.
Hospital Universitario Fundación Jiménez Díaz · ESInstituto de Salud Carlos III · ESUniversidad Francisco de Vitoria · ESHospital Universitario Virgen de la Arrixaca · ESResearch Institute Hospital 12 de Octubre · ESUniversidad Complutense de Madrid · ESInstituto Murciano de Investigación Biosanitaria · ESUniversidad Autónoma de Madrid · ESCentre for Biomedical Network Research on Rare Diseases · ESConsejería de Educación de la Junta de Castilla y León · ESHospital General Universitario Morales Meseguer · ESHospital Reina Sofía de Murcia · ESHospital Universitario 12 De Octubre · ESSanta Lucía University General Hospital · ESServicio Murciano de Salud · ESUniversidad San Pablo CEU · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rare variants affecting host defense against pathogens could be involved in COVID-19 severity and may help explain fatal outcomes in young and middle-aged patients. Our aim was to report the presence of rare genetic variants in certain genes, by using whole exome sequencing, in a selected group of COVID-19 patients under 65 years who required intubation or resulting in death (n = 44). To this end, different etiopathogenic mechanisms were explored using gene prioritization-based analysis in which genes involved in immune response, immunodeficiencies or blood coagulation were studied. We detected 44 different variants of interest, in 29 different patients (66%). Some of these variants were previously described as pathogenic and were located in genes mainly involved in immune response. A network analysis, including the 42 genes with candidate variants, showed three main components, consisting of 25 highly interconnected genes related to immune response and two additional networks composed by genes enriched in carbohydrate metabolism and in DNA metabolism and repair processes. In conclusion, we have detected candidate variants that may potentially influence COVID-19 outcome in our cohort of patients. Further studies are needed to confirm the ultimate role of the genetic variants described in the present study on COVID-19 severity.

Indexed as

COVID-19Immunologic Deficiency SyndromesAgedCohort StudiesExome SequencingGenetic Predisposition to DiseaseHumansMiddle Aged

Identifiers

PMID35725860
PMCPMC9208539
OpenAlexW4283167344

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.